scholarly journals New treatment of hepatitis C (Direct Acting Antiviral)

2019 ◽  
Author(s):  
Mohsen Akhondi-Meybodi
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Clinical Care ◽  
Diagnostic Procedures ◽  
Direct Acting Antiviral ◽  
New Treatment ◽  
Related Liver Disease ◽  
Acting Agent ◽  
Direct Acting

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention, recently in Iran new drug direct Acting agent (DAA) was developed that may be equivalent to original drugs that will hope to treat  HCV and eliminated HCV in future

Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia

2019 ◽  
Vol 71 (2) ◽  
pp. 281-288 ◽  
Author(s):  
Maryam Alavi ◽  
Matthew G. Law ◽  
Heather Valerio ◽  
Jason Grebely ◽  
Janaki Amin ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Disease Burden ◽  
New South ◽  
Direct Acting Antiviral ◽  
South Wales ◽  
Related Liver Disease ◽  
Direct Acting

scholarly journals Risk Factors and Hepatocellular Cancer Screening After Hepatitis C Virus Eradication

2021 ◽  
Vol 17 (28) ◽  
pp. 54-60
Author(s):  
A.O. Bueverov ◽  
◽  
P.O. Bogomolov ◽  
V.E. Syutkin ◽  
◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hepatocellular Cancer ◽  
Virus Eradication ◽  
Alcoholic Fatty Liver ◽  
Direct Acting Antiviral ◽  
Common Etiology ◽  
Almost All ◽  
Direct Acting

Hepatocellular cancer (HCC) usually develops against the background of chronic liver disease. Until recently, the most common etiology of HCC was infection with hepatitis C virus (HCV). The appearance of direct-acting antiviral drugs (DAAD) has become a big breakthrough in the treatment of HCV infection. A stable virological response can now be achieved in almost all treated patients, even in people at high risk of HCC, primarily with cirrhosis of the liver. At the same time, reports gradually began to accumulate about the continued risk of malignant transformation after successful therapy of DAAD. Simultaneously with the decrease in the burden of cirrhosis caused by HCV, the etiological role of non-alcoholic fatty liver disease (NAFLD) has sharply increased. Moreover, in a significant part of patients with NAFLD, HCC is formed at the pre-cirrhotic stage. These changes in the etiology and epidemiology of HCC suggest the revision of patient management tactics

Sign in / Sign up

Export Citation Format

Share Document